Category: Research
0.8-mm threshold for guiding the care of patients with thin primary melanomas
Importance: Most patients who present with primary cutaneous melanomas have thin tumors (≤1.0 mm in Breslow thickness, ie, pT1a and pT1b). Although their prognosis is generally considered to be excel…
Read more about '0.8-mm threshold for guiding the care of patients with thin primary melanomas'...
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite cli…
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
Background: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to …
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy
Background: Cancer immunotherapy has revolutionized melanoma treatment, but the high number of non-responders still emphasizes the need for improvement of therapy. One potential avenue for enhancing a…
Circulating tumor DNA assessment shows promising results in predicting and reflecting disease status during adjuvant therapy
Background: The introduction of adjuvant therapies for patients with resected cutaneous melanoma (CM) has increased the need for sensitive biomarkers for risk stratification and disease monitoring. Th…
Melacare nurse-led intervention feasible and acceptable for use with patients treated for early-stage melanoma
Background and purpose: We developed the Melacare nurse-led intervention, which combines education in skin self-examination as a resource-conscious approach to detecting recurrence and management of …
PDE4D drives rewiring of MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors
Background: Phosphodiesterase type 4D (PDE4D) breaks down cyclic AMP (cAMP) reducing the signaling of this intracellular second messenger which plays a major role in melanocyte pathophysiology. In adv…
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Background: In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on …
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo
Background: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, re…
E-cigarettes may contribute to the development of oral squamous cell carcinoma
Electronic cigarettes are widely used by young adults, yet their impact on oral health, specifically in the context of oral squamous cell carcinoma (OSCC), is poorly understood. This study aimed to ev…
Read more about 'E-cigarettes may contribute to the development of oral squamous cell carcinoma'...